The results of the clinical trial that led to FDA’s 2023 approval of repotrectinib (Augtyro) for lung cancers with ROS1 fusions have been published. The drug shrank tumors in 80% of people receiving the drug as an initial treatment.
The National Cancer Institute has launched a clinical trials network to evaluate emerging technologies for cancer screening. The Cancer Screening Research Network (CSRN) will support the Biden-Harris administration’s Cancer Moonshot℠ by investigating how to identify cancers earlier, when they may be easier to treat.
The CSRN will conduct rigorous, multicenter cancer screening trials with large and diverse populations in a variety of health care settings. Its goal is to reduce cancer-related illnesses and deaths. Learn more about the CSRN on this page from NCI’s Division of Cancer Prevention.
On January 25, 2024, NCI, with public and private partners, launched a new clinical trial network to gather data on a “self-collection” method of human papillomavirus (HPV) testing to prevent cervical cancer. This method, if determined viable, could improve how many people get screened for cervical cancer.
Mel Mann’s world changed in seconds as he was diagnosed with chronic myelogenous leukemia in 1995. He was 37 years old and told he likely had about 3 years to live. But Mel wasn’t giving up. "I saw a clinical trial as a chance to get tomorrow’s medicine today," Mel said.
Clinical Trials Information for Patients and Caregivers
Participating in a cancer prevention study can help find new ways to prevent cancer. Learn more about cancer prevention trials and what may be involved if you join one.
In this video, Raymond U. Osarogiagbon, M.D., talks about reaching out and taking the time to help one cancer patient and her family understand why a clinical trial might be the best care option.
This phase 1/2 clinical trial is testing a drug called zotiraciclib for people with high-grade glioma brain tumors that have mutations in the IDH1or IDH2genes and have come back after treatment. The first part of the trial will help doctors determine the lowest effective dose (optimal dose) of zotiraciclib. The second part of the trial will determine if the drug helps people live 12 months without their cancer getting worse (progression-free survival.)
This phase 2b trial tests whether a series of vaccines called Tri-Ad5 helps prevent colon and other cancers in people with a hereditary cancer syndrome called Lynch syndrome. The Tri-Ad5 vaccines will be given together with a drug called N805 that helps the vaccines last longer in the immune system.
This phase 2 trial will test an experimental drug combining decitabine and cedazuridine (Inqovi) to treat people with a cancer predisposition syndrome called BAP1 and early-stage mesothelioma that is not yet causing symptoms. Doctors want to see if the treatment stops the cancer from growing or shrinks the tumors.
